Taken together, our data indicate that a combination treatment of GC7 and ADI-PEG20 has significant potential clinical utility to minimize drug resistance in patients with ASS1-ve mesothelioma tumors, for which therapeutic options currently do not exist. The gene discussed is ASS1; the disease is mesothelioma.